Immune checkpoint inhibitors: a promising anticancer therapy

被引：137

作者：

Singh, Sima ^{[1
]}

Hassan, Daniel ^{[1
]}

Aldawsari, Hibah M. ^{[2
]}

Molugulu, Nagashekhara ^{[3
]}

Shukla, Rahul ^{[4
]}

Kesharwani, Prashant ^{[5
]}

机构：

[1] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, Private Bag X54001, Durban, South Africa

[2] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21589, Saudi Arabia

[3] Monash Univ, Sch Pharm, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia

[4] NIPER, Dept Pharmaceut, Raebareli 226301, India

[5] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India

来源：

DRUG DISCOVERY TODAY | 2020年 / 25卷 / 01期

关键词：

REGULATORY T-CELLS; PERIPHERAL-BLOOD; SUPPRESSOR-CELLS; BIOMARKERS; IMMUNOTHERAPY; MECHANISMS; RESISTANCE; CTLA-4; NANOCARRIERS; IPILIMUMAB;

D O I：

10.1016/j.drudis.2019.11.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of many cancers and have demonstrated their potential as 'cancer terminators'. However, ICI treatment also has constraints, such as its immune-related adverse events (irAEs) and therapeutic resistance. These drawbacks are gradually being overcome through better knowledge of the immune system, history of disease, duration of treatment, combinational drug regimes, adequate biomarkers, and effective patient response monitoring. In this review, we discuss the present ICI therapy landscape and its therapeutic outcomes for various diseases. We also highlight biomarkers related to the ICI response.

引用

页码：223 / 229

页数：7

共 60 条

[1]

[Anonymous], INT J CARDIOL HEART

[2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[3] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[4] Chronic inflammation and cancer: suppressing the suppressors [J].

Baniyash, Michal ;

Sade-Feldman, Moshe ;

Kanterman, Julia .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (01) :11-20

[5] Neoantigen-based cancer immunotherapy [J].

Bobisse, Sara ;

Foukas, Periklis G. ;

Coukos, George ;

Harari, Alexandre .

ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (14)

[6] NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control [J].

Boettcher, Jan P. ;

Bonavita, Eduardo ;

Chakravarty, Probir ;

Blees, Hanna ;

Cabeza-Cabrerizo, Mar ;

Sammicheli, Stefano ;

Rogers, Neil C. ;

Sahai, Erik ;

Zelenay, Santiago ;

Reis e Sousa, Caetano .

CELL, 2018, 172 (05) :1022-+

[7] PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review [J].

Brody, Robert ;

Zhang, Yiduo ;

Ballas, Marc ;

Siddiqui, Mohd Kashif ;

Gupta, Palvi ;

Barker, Craig ;

Midha, Anita ;

Walker, Jill .

LUNG CANCER, 2017, 112 :200-215

[8] Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature [J].

Cappelli, Laura C. ;

Gutierrez, Anna Kristina ;

Bingham, Clifton O., III ;

Shah, Ami A. .

ARTHRITIS CARE & RESEARCH, 2017, 69 (11) :1751-1763

[9] Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade [J].

Chen, Pei-Ling ;

Roh, Whijae ;

Reuben, Alexandre ;

Cooper, Zachary A. ;

Spencer, Christine N. ;

Prieto, Peter A. ;

Miller, John P. ;

Bassett, Roland L. ;

Gopalakrishnan, Vancheswaran ;

Wani, Khalida ;

De Macedo, Mariana Petaccia ;

Austin-Breneman, Jacob L. ;

Jiang, Hong ;

Chang, Qing ;

Reddy, Sangeetha M. ;

Chen, Wei-Shen ;

Tetzlaff, Michael T. ;

Broaddus, Russell J. ;

Davies, Michael A. ;

Gershenwald, Jeffrey E. ;

Haydu, Lauren ;

Lazar, Alexander J. ;

Patel, Sapna P. ;

Hwu, Patrick ;

Hwu, Wen-Jen ;

Diab, Adi ;

Glitza, Isabella C. ;

Woodman, Scott E. ;

Vence, Luis M. ;

Wistuba, Ignacio I. ;

Amaria, Rodabe N. ;

Kwong, Lawrence N. ;

Prieto, Victor ;

Davis, R. Eric ;

Ma, Wencai ;

Overwijk, Willem W. ;

Sharpe, Arlene H. ;

Hu, Jianhua ;

Futreal, P. Andrew ;

Blando, Jorge ;

Sharma, Padmanee ;

Allison, James P. ;

Chin, Lynda ;

Wargo, Jennifer A. .

CANCER DISCOVERY, 2016, 6 (08) :827-837

[10] Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells [J].

Chmielewski, Markus ;

Hombach, Andreas A. ;

Abken, Hinrich .

FRONTIERS IN IMMUNOLOGY, 2013, 4

← 1 2 3 4 5 6 →